Works matching AU de Groot, Derk Jan A.

Results: 35

Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery Protocol.

Published in:

Oncologist, 2024, v. 29, n. 5, p. 431, doi. 10.1093/oncolo/oyad320

By:

Spiekman, Ilse A C;
Geurts, Birgit S;
Zeverijn, Laurien J;
Wit, Gijs F de;
van der Noort, Vincent;
Roepman, Paul;
Leng, Wendy W J de;
Jansen, Anne M L;
Kusters, Benno;
Beerepoot, Laurens V;
Vos, Filip Y F L de;
Groot, Derk-Jan A de;
Groot, Jan Willem B de;
Hoeben, Ann;
Buter, Jan;
Gelderblom, Hans A J;
Voest, Emile E;
Verheul, Henk M W

Publication type:

Article

Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition.

Published in:

Rheumatology, 2016, v. 55, n. 6, p. 1143, doi. 10.1093/rheumatology/kew063

By:

van den Brom, Rob R. H.;
Abdulahad, Wayel H.;
Rutgers, Abraham;
Kroesen, Bart-Jan;
Roozendaal, Caroline;
A. de Groot, Derk Jan;
Schröder, Carolien P.;
Hospers, Geke A. P.;
Brouwer, Elisabeth

Publication type:

Article

First-line everolimus and cisplatin in patients with advanced extrapulmonary neuroendocrine carcinoma: a nationwide phase 2 single-arm clinical trial.

Published in:

Therapeutic Advances in Medical Oncology, 2022, p. 1, doi. 10.1177/17588359221077088

By:

Levy, Sonja;
Verbeek, Wieke H.M.;
Eskens, Ferry A.L.M.;
van den Berg, José G.;
de Groot, Derk Jan A.;
van Leerdam, Monique E.;
Tesselaar, Margot E.T.

Publication type:

Article

89Zr-3,2-HOPO-Mesothelin Antibody PET Imaging Reflects Tumor Uptake of Mesothelin-Targeted 227Th-Conjugate Therapy in Mice.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 11, p. 1715, doi. 10.2967/jnumed.121.263079

By:

Broer, Linda N.;
Knapen, Daan G.;
Suurs, Frans V.;
Moen, Ingrid;
Giesen, Danique;
Waaijer, Stijn J. H.;
Indrevoll, Baard;
Ellingsen, Christine;
Kristian, Alexander;
Cuthbertson, Alan S.;
de Groot, Derk-Jan A.;
Cole, Patricia E.;
de Vries, Elisabeth G. E.;
Hagemann, Urs B.;
Lub-de Hooge, Marjolijn N.

Publication type:

Article

89Zr-3,2-HOPO-mesothelin antibody PET imaging 1 reflects tumor uptake of mesothelin targeted 227Th-conjugate therapy in mice.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.121.263079

By:

Broer, Linda N.;
Knapen, Daan G.;
Suurs, Frans Valentijn;
Moen, Ingrid;
Giesen, Danique;
Waaijer, Stijn J. H.;
Indrevoll, Baard;
Ellingsen, Christine;
Kristian, Alexander;
Cuthbertson, Alan S.;
de Groot, Derk-Jan A.;
Cole, Patricia E.;
de Vries, Elisabeth G. E.;
Hagemann, Urs B.;
Lub-de Hooge, Marjolijn N.

Publication type:

Article

89Zr-3,2-HOPO-mesothelin antibody PET imaging reflects tumor uptake of mesothelin targeted 227Th-conjugate therapy in mice.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.121.263079

By:

Broer, Linda N.;
Knapen, Daan G.;
Suurs, Frans V.;
Moen, Ingrid;
Giesen, Danique;
Waaijer, Stijn J. H.;
Indrevoll, Baard;
Ellingsen, Christine;
Kristian, Alexander;
Cuthbertson, Alan S.;
de Groot, Derk-Jan A.;
Cole, Patricia E.;
de Vries, Elisabeth G. E.;
Hagemann, Urs B.;
Lub-de Hooge, Marjolijn N.

Publication type:

Article

89Zr-3,2-HOPO-mesothelin antibody PET imaging reflects tumor uptake of mesothelin targeted 227Th-conjugate therapy in mice.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 7, p. 1, doi. 10.2967/jnumed.121.263079

By:

Broer, Linda N.;
Knapen, Daan G.;
Suurs, Frans V.;
Moen, Ingrid;
Giesen, Danique;
Waaijer, Stijn J. H.;
Indrevoll, Baard;
Ellingsen, Christine;
Kristian, Alexander;
Cuthbertson, Alan S.;
de Groot, Derk-Jan A.;
Cole, Patricia E.;
de Vries, Elisabeth G. E.;
Hagemann, Urs B.;
Lub-de Hooge, Marjolijn N.

Publication type:

Article

89Zr-3,2-HOPO-mesothelin antibody PET imaging 1 reflects tumor uptake of mesothelin targeted 227Th-conjugate therapy in mice.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 6, p. 1, doi. 10.2967/jnumed.121.263079

By:

Broer, Linda N.;
Knapen, Daan G.;
Suurs, Frans V.;
Moen, Ingrid;
Giesen, Danique;
Waaijer, Stijn J. H.;
Indrevoll, Baard;
Ellingsen, Christine;
Kristian, Alexander;
Cuthbertson, Alan S.;
de Groot, Derk-Jan A.;
Cole, Patricia E.;
de Vries, Elisabeth G. E.;
Hagemann, Urs B.;
Lub-de Hooge, Marjolijn N.

Publication type:

Article

89Zr-3,2-HOPO-mesothelin antibody PET imaging reflects tumor uptake of mesothelin targeted 227Th-conjugate therapy in mice.

Published in:

Journal of Nuclear Medicine, 2022, v. 63, n. 5, p. 1, doi. 10.2967/jnumed.121.263079

By:

Broer, Linda N.;
Knapen, Daan G.;
Suurs, Frans V.;
Moen, Ingrid;
Giesen, Danique;
Waaijer, Stijn J. H.;
Indrevoll, Baard;
Ellingsen, Christine;
Kristian, Alexander;
Cuthbertson, Alan S.;
de Groot, Derk-Jan A.;
Cole, Patricia E.;
de Vries, Elisabeth G. E.;
Hagemann, Urs B.;
Lub-de Hooge, Marjolijn N.

Publication type:

Article

Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.

Published in:

Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.120.259036

By:

Suurs, Frans V.;
Lorenczewski, Grit;
Bailis, Julie M.;
Stienen, Sabine;
Friedrich, Matthias;
Lee, Fei;
van der Vegt, Bert;
de Vries, Elisabeth G. E.;
de Groot, Derk Jan A.;
Lub-de Hooge, Marjolijn N.

Publication type:

Article

Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.

Published in:

Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.120.259036

By:

Suurs, Frans V.;
Lorenczewski, Grit;
Bailis, Julie M.;
Stienen, Sabine;
Friedrich, Matthias;
Lee, Fei;
der Vegt, Bert van;
de Vries, Elisabeth G. E.;
de Groot, Derk Jan A.;
Lub-de Hooge, Marjolijn N.

Publication type:

Article

Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.

Published in:

Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.120.259036

By:

Suurs, Frans V.;
Lorenczewski, Grit;
Bailis, Julie M.;
Stienen, Sabine;
Friedrich, Matthias;
Lee, Fei;
van der Vegt, Bert;
de Vries, Elisabeth G. E.;
de Groot, Derk Jan A.;
Lub-de Hooge, Marjolijn N.

Publication type:

Article

Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.

Published in:

Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.120.259036

By:

Suurs, Frans V.;
Lorenczewski, Grit;
Bailis, Julie M.;
Stienen, Sabine;
Friedrich, Matthias;
Fei Lee;
van der Vegt, Bert;
de Vries, Elisabeth G. E.;
de Groot, Derk Jan A.;
Lub-de Hooge, Marjolijn N.

Publication type:

Article

Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.

Published in:

Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.120.259036

By:

Suurs, Frans V.;
Lorenczewski, Grit;
Bailis, Julie M.;
Stienen, Sabine;
Friedrich, Matthias;
Fei Lee;
van der Vegt, Bert;
de Vries, Elisabeth G. E.;
de Groot, Derk Jan A.;
Lub-de Hooge, Marjolijn N.

Publication type:

Article

Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.

Published in:

Journal of Nuclear Medicine, 2021, v. 62, n. 6, p. 1, doi. 10.2967/jnumed.120.259036

By:

Suurs, Frans V.;
Lorenczewski, Grit;
Bailis, Julie M.;
Stienen, Sabine;
Friedrich, Matthias;
Lee, Fei;
van der Vegt, Bert;
de Vries, Elisabeth G. E.;
de Groot, Derk Jan A.;
Lub-de Hooge, Marjolijn N.

Publication type:

Article

Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.

Published in:

Journal of Nuclear Medicine, 2021, v. 62, n. 5, p. 1, doi. 10.2967/jnumed.120.259036

By:

Suurs, Frans V.;
Lorenczewski, Grit;
Bailis, Julie M.;
Stienen, Sabine;
Friedrich, Matthias;
Lee, Fei;
van der Vegt, Bert;
de Vries, Elisabeth G. E.;
de Groot, Derk Jan A.;
Lub-de Hooge, Marjolijn N.

Publication type:

Article

Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.

Published in:

Journal of Nuclear Medicine, 2020, v. 61, n. 12, p. 1, doi. 10.2967/jnumed.120.241877

By:

Suurs, Frans V.;
Lorenczewski, Grit;
Stienen, Sabine;
Friedrich, Matthias;
de Vries, Elisabeth G. E.;
de Groot, Derk Jan A.;
Hooge, Marjolijn N. Lub-de

Publication type:

Article

Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.

Published in:

Journal of Nuclear Medicine, 2020, v. 61, n. 11, p. 1, doi. 10.2967/jnumed.120.241877

By:

Suurs, Frans V.;
Lorenczewski, Grit;
Stienen, Sabine;
Friedrich, Matthias;
de Vries, Elisabeth G. E.;
de Groot, Derk Jan A.;
Lub-de Hooge, Marjolijn N.

Publication type:

Article

Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.

Published in:

Journal of Nuclear Medicine, 2020, v. 61, n. 10, p. 1, doi. 10.2967/jnumed.120.241877

By:

Suurs, Frans V.;
Lorenczewski, Grit;
Stienen, Sabine;
Friedrich, Matthias;
de Vries, Elisabeth G. E.;
de Groot, Derk Jan A.;
Lub-de Hooge, Marjolijn N.

Publication type:

Article

Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.

Published in:

Journal of Nuclear Medicine, 2020, v. 61, n. 9, p. 1, doi. 10.2967/jnumed.120.24187

By:

Suurs, Frans V.;
Lorenczewski, Grit;
Stienen, Sabine;
Friedrich, Matthias;
de Vries, Elisabeth G. E.;
de Groot, Derk Jan A.;
Lub-de Hooge, Marjolijn N.

Publication type:

Article

Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.

Published in:

Journal of Nuclear Medicine, 2020, v. 61, n. 7, p. 1, doi. 10.2967/jnumed.120.241877

By:

Suurs, Frans V.;
Lorenczewski, Grit;
Stienen, Sabine;
Friedrich, Matthias;
de Vries, Elisabeth G. E.;
de Groot, Derk Jan A.;
Hooge, Marjolijn N. Lub-de

Publication type:

Article

Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.

Published in:

Journal of Nuclear Medicine, 2020, v. 61, n. 6, p. 1, doi. 10.2967/jnumed.120.241877

By:

Suurs, Frans V.;
Lorenczewski, Grit;
Stienen, Sabine;
Friedrich, Matthias;
de Vries, Elisabeth G. E.;
de Groot, Derk Jan A.;
Lub-de Hooge, Marjolijn N.

Publication type:

Article

Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.

Published in:

Journal of Nuclear Medicine, 2020, v. 61, n. 5, p. 1, doi. 10.2967/jnumed.120.241877

By:

Suurs, Frans V.;
Lorenczewski, Grit;
Stienen, Sabine;
Friedrich, Matthias;
de Vries, Elisabeth G. E.;
de Groot, Derk Jan A.;
Lub-de Hooge, Marjolijn N.

Publication type:

Article

Data-Driven Prioritization and Review of Targets for Molecular-Based Theranostic Approaches in Pancreatic Cancer.

Published in:

Journal of Nuclear Medicine, 2017, v. 58, n. 12, p. 1899, doi. 10.2967/jnumed.117.198440

By:

Koller, Marjory;
Hartmans, Elmire;
de Groot, Derk Jan A.;
Zhao, Xiao Juan;
van Dam, Gooitzen M.;
Nagengast, Wouter B.;
Fehrmann, Rudolf S. N.

Publication type:

Article

Theranostics Using Antibodies and Antibody-Related Therapeutics.

Published in:

Journal of Nuclear Medicine, 2017, v. 58, p. 83S, doi. 10.2967/jnumed.116.186940

By:

Moek, Kirsten L.;
Giesen, Danique;
Kok, Iris C.;
de Groot, Derk Jan A.;
Jalving, Mathilde;
Fehrmann, Rudolf S. N.;
Lub-de Hooge, Marjolijn N.;
Brouwers, Adrienne H.;
de Vries, Elisabeth G. E.

Publication type:

Article

Radiolabeled Monoclonal Antibody Against Colony-Stimulating Factor 1 Receptor Specifically Distributes to the Spleen and Liver in Immunocompetent Mice.

Published in:

Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.786191

By:

Waaijer, Stijn J. H.;
Suurs, Frans V.;
Hau, Cheei-Sing;
Vrijland, Kim;
de Visser, Karin E.;
de Groot, Derk Jan A.;
de Vries, Elisabeth G. E.;
Lub-de Hooge, Marjolijn N.;
Schröder, Carolina P.

Publication type:

Article

Manual Versus Artificial Intelligence-Based Segmentations as a Pre-processing Step in Whole-body PET Dosimetry Calculations.

Published in:

Molecular Imaging & Biology, 2023, v. 25, n. 2, p. 435, doi. 10.1007/s11307-022-01775-5

By:

van Sluis, Joyce;
Noordzij, Walter;
de Vries, Elisabeth G. E.;
Kok, Iris C.;
de Groot, Derk Jan A.;
Jalving, Mathilde;
Lub-de Hooge, Marjolijn N.;
Brouwers, Adrienne H.;
Boellaard, Ronald

Publication type:

Article

Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis.

Published in:

International Journal of Cancer, 2006, v. 118, n. 8, p. 1892, doi. 10.1002/ijc.21580

By:

Hougardy, Brigitte M.T.;
Maduro, John H.;
van der Zee, Ate G.J.;
de Groot, Derk Jan A.;
van den Heuvel, Fiona A.J.;
de Vries, Elisabeth G.E.;
de Jong, Steven

Publication type:

Article

Comparison of [18F]DOPA and [68Ga]DOTA-TOC as a PET imaging tracer before peptide receptor radionuclide therapy.

Published in:

European Journal of Hybrid Imaging, 2022, v. 6, n. 1, p. 1, doi. 10.1186/s41824-022-00133-6

By:

Veenstra, Emile B.;
Brouwers, Adrienne H.;
de Groot, Derk Jan A.;
Hofland, Johannes;
Walenkamp, Annemiek M. E.;
Brabander, Tessa;
Zandee, Wouter T.;
Noordzij, Walter

Publication type:

Article

Phase II study (KAMELEON) of single‐agent T‐DM1 in patients with HER2‐positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma.

Published in:

Cancer Medicine, 2023, v. 12, n. 11, p. 12071, doi. 10.1002/cam4.5893

By:

de Vries, Elisabeth G. E.;
Rüschoff, Josef;
Lolkema, Martijn;
Tabernero, Josep;
Gianni, Luca;
Voest, Emile;
de Groot, Derk Jan A.;
Castellano, Daniel;
Erb, Gilles;
Naab, Julia;
Donica, Margarita;
Deurloo, Regula;
van der Heijden, Michiel S.;
Viale, Giuseppe

Publication type:

Article

Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial.

Published in:

JAMA Surgery, 2024, v. 159, n. 4, p. 429, doi. 10.1001/jamasurg.2023.7872

By:

Mackay, Tara M.;
Latenstein, Anouk E. J.;
Augustinus, Simone;
van der Geest, Lydia G.;
Bogte, Auke;
Bonsing, Bert A.;
Cirkel, Geert A.;
Hol, Lieke;
Busch, Olivier R.;
den Dulk, Marcel;
van Driel, Lydi M. J.W.;
Festen, Sebastiaan;
de Groot, Derk-Jan A.;
de Groot, Jan-Willem B.;
Groot Koerkamp, Bas;
Haj Mohammad, Nadia;
Haver, Joyce T.;
van der Harst, Erwin;
de Hingh, Ignace H.;
Homs, Marjolein Y. V.

Publication type:

Article

Patient-Derived Organoid Models of Human Neuroendocrine Carcinoma.

Published in:

Frontiers in Endocrinology, 2021, v. 11, p. N.PAG, doi. 10.3389/fendo.2021.627819

By:

Dijkstra, Krijn K.;
van den Berg, José G.;
Weeber, Fleur;
van de Haar, Joris;
Velds, Arno;
Kaing, Sovann;
Peters, Dennis D. G. C.;
Eskens, Ferry A. L. M.;
de Groot, Derk-Jan A.;
Tesselaar, Margot E. T.;
Voest, Emile E.

Publication type:

Article

Potential, Limitations and Risks of Cannabis-Derived Products in Cancer Treatment.

Published in:

Cancers, 2023, v. 15, n. 7, p. 2119, doi. 10.3390/cancers15072119

By:

Woerdenbag, Herman J.;
Olinga, Peter;
Kok, Ellen A.;
Brugman, Donald A. P.;
van Ark, Ulrike F.;
Ramcharan, Arwin S.;
Lebbink, Paul W.;
Hoogwater, Frederik J. H.;
Knapen, Daan G.;
de Groot, Derk Jan A.;
Nijkamp, Maarten W.

Publication type:

Article

Self‐Targeted Co‐Delivery of an Antibiotic and a Cancer‐Chemotherapeutic from Synthetic Liposomes for the Treatment of Infected Tumors.

Published in:

Advanced Functional Materials, 2023, v. 33, n. 32, p. 1, doi. 10.1002/adfm.202215153

By:

Wang, Da‐Yuan;
Cao, Yuanlong;
Yang, Guang;
Zhang, Siyu;
van der Mei, Henny C.;
Ren, Yijin;
van Kooten, Theo G.;
de Groot, Derk‐Jan A.;
de Haan, Jacco J.;
Shi, Linqi;
Busscher, Henk J.

Publication type:

Article

Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy.

Published in:

Cancer & Metastasis Reviews, 2020, v. 39, n. 3, p. 999, doi. 10.1007/s10555-020-09876-9

By:

Boonstra, Pieter A.;
Wind, Thijs T.;
van Kruchten, Michel;
Schuuring, Ed;
Hospers, Geke A. P.;
van der Wekken, Anthonie J.;
de Groot, Derk-Jan;
Schröder, Carolien P.;
Fehrmann, Rudolf S. N.;
Reyners, Anna K. L.

Publication type:

Article

Works matching AU de Groot, Derk Jan A.

Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery Protocol.

Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition.

First-line everolimus and cisplatin in patients with advanced extrapulmonary neuroendocrine carcinoma: a nationwide phase 2 single-arm clinical trial.

<sup>89</sup>Zr-3,2-HOPO-Mesothelin Antibody PET Imaging Reflects Tumor Uptake of Mesothelin-Targeted <sup>227</sup>Th-Conjugate Therapy in Mice.

<sup>89</sup>Zr-3,2-HOPO-mesothelin antibody PET imaging 1 reflects tumor uptake of mesothelin targeted <sup>227</sup>Th-conjugate therapy in mice.

<sup>89</sup>Zr-3,2-HOPO-mesothelin antibody PET imaging reflects tumor uptake of mesothelin targeted <sup>227</sup>Th-conjugate therapy in mice.

<sup>89</sup>Zr-3,2-HOPO-mesothelin antibody PET imaging reflects tumor uptake of mesothelin targeted <sup>227</sup>Th-conjugate therapy in mice.

<sup>89</sup>Zr-3,2-HOPO-mesothelin antibody PET imaging 1 reflects tumor uptake of mesothelin targeted <sup>227</sup>Th-conjugate therapy in mice.

<sup>89</sup>Zr-3,2-HOPO-mesothelin antibody PET imaging reflects tumor uptake of mesothelin targeted <sup>227</sup>Th-conjugate therapy in mice.

Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.

Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.

Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.

Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.

Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.

Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.

Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.

Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.

Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.

Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.

Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.

Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.

Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.

Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.

Data-Driven Prioritization and Review of Targets for Molecular-Based Theranostic Approaches in Pancreatic Cancer.

Theranostics Using Antibodies and Antibody-Related Therapeutics.

Radiolabeled Monoclonal Antibody Against Colony-Stimulating Factor 1 Receptor Specifically Distributes to the Spleen and Liver in Immunocompetent Mice.

Manual Versus Artificial Intelligence-Based Segmentations as a Pre-processing Step in Whole-body PET Dosimetry Calculations.

Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis.

Comparison of [<sup>18</sup>F]DOPA and [<sup>68</sup>Ga]DOTA-TOC as a PET imaging tracer before peptide receptor radionuclide therapy.

Phase II study (KAMELEON) of single‐agent T‐DM1 in patients with HER2‐positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma.

Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial.

Patient-Derived Organoid Models of Human Neuroendocrine Carcinoma.

Potential, Limitations and Risks of Cannabis-Derived Products in Cancer Treatment.

Self‐Targeted Co‐Delivery of an Antibiotic and a Cancer‐Chemotherapeutic from Synthetic Liposomes for the Treatment of Infected Tumors.

Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy.